2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - 343-345
Technology and Procedures, Bioinformatics, Treatment Considerations, Combination Therapy, Biological Therapies, (CAR)-T Cell Therapies, Biological Processes, Immune Mechanism, Diseases, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Young Adult
PAPER

428 Closing the escape routes:  Dual CAR-T cell targeting of FL and its tumor microenvironment

Maria Ros, Claudia Di Trani, PhD2, Paul Buckley, PhD3, Ferran Araujo-Ayala4, Marta Giménez-Alejandre5, Salut Colell6, Juan Manuel Jimenez-Aguilar7, Armando Lopez-Guillermo, MD, PhD8, Alvaro Urbano-Ispizua, MD, PhD9, Julio Delgado, MD10, Manel Juan, MD, PhD11, Elias Campo, MD, PhD12, Piers E M Patten, MB ChB PhD13, Mitchell R. Smith, MD, PhD14, Alba Rodriguez-Garcia15, Sonia Guedan, PhD16, Patricia Perez Galan, PhD17
1 Centro Investigación Biomédica En Red - Oncología (CIBER-ONC), Madrid, Spain, Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS) - Fundació Clínic per la Recerca Biomèdica, Barcelona, Spain
2 Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS) - Fundació Clínic per la Recerca Biomèdica, Barcelona, Spain
3 Guy's Cancer Centre, London, United Kingdom, King's College London, London, United Kingdom
4 University College of London, London, United Kingdom
5 Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS) - Fundació Clínic per la Recerca Biomèdica, Barcelona, Spain
6 Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS) - Fundació Clínic per la Recerca Biomèdica, Barcelona, Spain
7 Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS) - Fundació Clínic per la Recerca Biomèdica, Barcelona, Spain
8 Facultat De Medicina-Universitat De Barcelona, Barcelona, Spain, Hospital Clínic De Barcelona, Barcelona, Spain, Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS) - Fundació Clínic per la Recerca Biomèdica, Barcelona, Spain
9 Facultat De Medicina-Universitat De Barcelona, Barcelona, Spain, Facultat De Medicina-Universitat De Barcelona, Barcelona, Spain, Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS) - Fundació Clínic per la Recerca Biomèdica, Barcelona, Spain
10 Centro Investigación Biomédica En Red - Oncología (CIBER-ONC), Madrid, Spain, Facultat De Medicina-Universitat De Barcelona, Barcelona, Spain, Hospital Clínic De Barcelona, Barcelona, Spain, Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS) - Fundació Clínic per la Recerca Biomèdica, Barcelona, Spain
11 Facultat De Medicina-Universitat De Barcelona, Barcelona, Spain, Hospital Clínic De Barcelona, Barcelona, Spain, Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS) - Fundació Clínic per la Recerca Biomèdica, Barcelona, Spain
12 Centro Investigación Biomédica En Red - Oncología (CIBER-ONC), Madrid, Spain, Facultat De Medicina-Universitat De Barcelona, Barcelona, Spain, Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS) - Fundació Clínic per la Recerca Biomèdica, Barcelona, Spain
13 Guy's Cancer Centre, London, United Kingdom, King's College London, London, United Kingdom
14 Follicular Lymphoma Foundation, London, United Kingdom
15 Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS) - Fundació Clínic per la Recerca Biomèdica, Barcelona, Spain
16 Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS) - Fundació Clínic per la Recerca Biomèdica, Barcelona, Spain
17 Centro Investigación Biomédica En Red - Oncología (CIBER-ONC), Madrid, Spain, Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS) - Fundació Clínic per la Recerca Biomèdica, Barcelona, Spain
Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin Lymphoma (B-NHL). Although most patients achieve complete responses after first-line therapy, a significant proportion eventually relapse, leading to poorer clinical outcomes and an increased risk of histological transformation into aggressive lymphoma. In the relapsed/refractory (R/R) setting, CD19 CAR-T cell therapy has improved clinical outcomes. Nevertheless, many patients still relapse after treatment, highlighting the need to better understand resistance mechanisms and develop improved therapeutic strategies.

The tumor microenvironment (TME) plays a pivotal role in the development, progression, and therapeutic resistance of FL. Malignant B cells evade immune surveillance by actively recruiting immunosuppressive cells, predominantly tumor-associated macrophages (TAMs), before encountering cytotoxic T cells, highlighting the critical role of the myeloid compartment in establishing an immune-privileged niche (Lin et al., Blood, 2024). Previous studies in B-cell non-Hodgkin lymphoma have identified CSF1R⁺ TAMs as major contributors to CD19 CAR-T cell resistance. These subset of macrophages promote CAR-T cell dysfunction, correlating with inferior clinical responses (Stahl et al.; Cancer Cell, 2025). 

Considering that CD19 CAR-T is applied to R/R FL patients, we first characterized the immune microenvironment in this high-risk population. Thus, we performed Imaging Mass Cytometry (HyperionTM) using a panel of 29 antibodies on paired diagnosis versus first-line treatment relapse FL samples (n=14). This analysis revealed an enrichment of M2-like macrophages in relapse samples, with a significance increased proportion of folate-receptor β (FRβ+) macrophages. Furthermore, the proliferative (Ki67+) FRβ+ macrophages subset was associated with a larger proportion of stromal cellular compartment in their cellular neighborhood.

To assess the functional role of this population, we established an in vitro co-culture system comprising macrophages, FL cell lines, and CD19 CAR-T cells. The presence of FRβ+ M2 macrophages impaired CD19 CAR-T cell activity, supporting a role for this myeloid subset in mediating immune resistance in the FL context.

To translate these findings into a therapeutic strategy, we developed dual-targeting CD19-FRβ CAR-T cells using our academic CD19 CAR-T product, ARI-0001 (Martínez-Cibrián et al., HemaSphere, 2025), as the backbone. We generated two products, using either a unique a bicistronic vector or a co-transduction approach to target malignant B cells and modulate the immunosuppressive TME. This dual CAR-T cell approach demonstrated the ability to deplete M2 macrophages while preserving anti-tumor activity against antigen-presenting cell models (K562) and FL cell lines (WSU-FSCCL and SC-1). We next validated these results in our patient-derived lymphoma tumoroid (PDLT) model (Gimenez R, Blood (2024) 144 (supp1 ;1613)). This system integrates FL primary samples and macrophages autologous to CAR-T, all embedded in Collagen I together with follicular dendritic cells to mimic germinal center support.  These TAMs polarize to M2-like expressing high levels of FRβ. Noteworthy, dual CD19-FRβ CAR-T cells maintained CD19-directed cytotoxicity while contributing to remodelling the TME.

In order to assess the dual CAR-T bioactivity in vivo, a murine bicistronic CD19-FRβ CAR-T product was generated. Using a previously described FL syngeneic mouse model (Isshiki et al.; Cancer Cell, 2025), this construct efficiently depleted murine M2 macrophages in vitro while retaining CD19-targeting capabilities. The delivery of the dual CAR-T product promoted long-lasting tumor control with no associated toxicities.

In summary, FRβ+ macrophages define a biologically distinct tumor ecosystem associated with R/R FL. These findings provide a rationale for dual CD19-FRβ CAR-T cell therapy as a strategy to enhance tumor control and overcome microenvironment-driven resistance in R/R FL patients.
 
Maria Ros: No relevant conflicts of interest to declare.